Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02956005 · ClinicalTrials.gov registry record · NA
Envarsus XR in African American Renal Transplant Recipients
A NA study, sponsored by Georgetown University.
- Terminated
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT02956005 is a NA study that was terminated before completion, run by Georgetown University. The registered enrollment target is 18 participants.
The verdict
NCT02956005, a NA study, was terminated before completion, sponsored by Georgetown University.
- TERMINATED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to collect data prospectively on African American patients who are taking the immunosuppressant Envarsus post kidney transplant. We are looking to see if African American renal transplant recipients that receive Envarsus will have less tubular injury and calcenurin inhibitor toxicity compared with patients that receive tacrolimus IR. African americans have the higher rates of CYP3A5 which is associated with the need of higher tacrolimus dose to achieve an adequate level and this many times is associated with signs and symptoms of tacrolimus toxicity such as tremors, headaches and neuropathies. The retrospective cohort will be African American patients that will be matched by age, gender, type of kidney transplant (living vs deceased) and level of sensitization
Interventions
- DRUG ENVARSUS®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-09 |
| Est. Completion | 2018-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02956005
The ClinicalTrials.gov registry entry for NCT02956005 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ENVARSUS® is the first listed.
NCT02956005 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02956005 about?
NCT02956005 is a clinical study titled "Envarsus XR in African American Renal Transplant Recipients". The purpose of this study is to collect data prospectively on African American patients who are taking the immunosuppressant Envarsus post kidney transplant. We are looking to see if African American renal transplant recipients that receive Envarsus will have less tubular injury and calcenurin inhib...
What is the current status of trial NCT02956005?
This trial is currently terminated. It is a NA study. The enrollment target is 18 participants. The study started on 2016-09. Estimated completion is 2018-09.
What interventions are being tested in trial NCT02956005?
The interventions under investigation include: ENVARSUS® (DRUG).
Who is sponsoring clinical trial NCT02956005?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.